JP2004359571A - Cyclic amp (camp) production inhibitor - Google Patents

Cyclic amp (camp) production inhibitor Download PDF

Info

Publication number
JP2004359571A
JP2004359571A JP2003157577A JP2003157577A JP2004359571A JP 2004359571 A JP2004359571 A JP 2004359571A JP 2003157577 A JP2003157577 A JP 2003157577A JP 2003157577 A JP2003157577 A JP 2003157577A JP 2004359571 A JP2004359571 A JP 2004359571A
Authority
JP
Japan
Prior art keywords
extract
family
camp
ficus
cyclic amp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003157577A
Other languages
Japanese (ja)
Inventor
Rikako Suzuki
理香子 鈴木
Kenichi Umishio
健一 海塩
Osamu Moro
修 茂呂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiseido Co Ltd
Original Assignee
Shiseido Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shiseido Co Ltd filed Critical Shiseido Co Ltd
Priority to JP2003157577A priority Critical patent/JP2004359571A/en
Publication of JP2004359571A publication Critical patent/JP2004359571A/en
Withdrawn legal-status Critical Current

Links

Landscapes

  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide a cyclic AMP (cAMP) production inhibitor which has a cyclic AMP (cAMP) production-inhibiting effect and has excellent safety. <P>SOLUTION: This cyclic AMP (cAMP) production inhibitor is characterized by containing one or more plants (extracts) selected from Terminalia chebula, Terminalia belerica, Ocimum basillicum, Bergenia ciliata, Anacardium occidentale, Dillenia indica, Boswellia serrata, Grewia salutaris, Woodfordia floribunda, Cassia angustifolia, Ficus ribes, Gunnera macrophylla, Ficus religiosa, Areca catechu, Stryphlinodendron barbatiman, Ficus bengalensis, Quercus brachystachys, Acacia fornensia, Cassia fistula, Salmalia malabalica, Buddleja cordata, and the others as an active ingredient. <P>COPYRIGHT: (C)2005,JPO&NCIPI

Description

【0001】
【発明の属する技術分野】
本発明は特定の植物抽出物を含有するサイクリックAMP(cAMP)産生阻害剤に関する。本発明のサイクリックAMP(cAMP)産生阻害剤は優れたサイクリックAMP(cAMP)産生阻害効果を有し、かつ安全性に優れたものである。
【0002】
【従来の技術】
皮膚のしみ、そばかす等の色素沈着は、ホルモンの異常分泌、紫外線や炎症性の刺激等により、表皮色素細胞内メラニン産生情報伝達経路が活性化し、メラニン産生主要酵素であるチロシナーゼの産生、活性発現が亢進した結果、メラニンが表皮に過剰に沈着するため生ずる。
【0003】
このようなしみ、そばかすを防ぐ手段として、メラニン産生主要酵素であるチロシナーゼの活性を阻害する物質が従来用いられてきた。具体的にはチロシナーゼ活性発現に必須である銅イオンを捕捉することを作用機序とするコウジ酸、エラグ酸等を配合してなるクリーム、ローション等の局所への塗布や、基質チロシンと類似構造を有し、チロシナーゼ競合阻害剤として働くハイドロキノン誘導体、レゾルシノール誘導体等を配合してなるクリーム、ローション等の局所への塗布、あるいは上記以外の作用機序を有する物としては、メラニン前駆体であるドーパキノンをドーパに還元することをメラニン産生抑制機序とするL−アスコルビン酸の投与が行われてきた。
【0004】
前記の物質は産生されたチロシナーゼに対して、またはチロシナーゼ活性発現により産生されたドーパキノンに作用するものであり、チロシナーゼ産生そのものを阻害するものではなかった。そのため、効果自体およびその持続性が弱いという難点があった。また、L−アスコルビン酸に関しては原体および基剤中での安定性が悪く、しみ、そばかすを十分に防ぐ効果を得るためには大量の投与が必要とされている。
【0005】
近年、植物抽出液中に含有される各種の活性成分が注目されている。多くの植物に含有されるポリフェノール類の抗酸化作用を始めとして、抗腫瘍作用等様々の作用が報告されている。美白作用を有する植物抽出液もさまざまなものが探索されている。
美白効果を有する植物として、従来より金桜子、営実、地楡、ユキノシタなどが知られているが、これらの植物抽出液もまたチロシナーゼ活性を阻害することをその作用機序としたものであり、美白作用およびその持続性は満足できるものではなかった。
一方、情報伝達経路に作用し、メラニンの産生自身を阻害する物質として、一酸化窒素経路阻害作用を有するかきょく、プロテインカイネースC経路阻害作用を有するカミツレ等が報告されている。しかしながらこれらの伝達経路はメラニン産生への関与が低く、顕著なメラニン産生阻害を得ることは困難であり、より優れた植物抽出薬効剤の開発が期待されていた。
本出願人はバラ科のセイヨウバラがサイクリックAMP(cAMP)の産生を阻害して美白作用を有することをすでに見出している(例えば、特許文献1参照。)。
【0006】
【特許文献1】
特開2002−29959号公報(段落[0021]〜[0038])
【0007】
【発明が解決しようとする課題】
本発明者らは上記事情に鑑み鋭意研究を重ねた結果、特定の植物およびその抽出物にメラニン産生への関与が高いアデニレートサイクレース経路阻害効果があることを見出し、本発明を完成するに至った。
【0008】
【課題を解決するための手段】
すなわち本発明は、シクンシ科 Terminalia chebula、シクンシ科 Terminalia belerica、シソ科 Ocimum basillicum、ユキノシタ科 Bergenia ciliata、ウルシ科 Anacardium occidentale、ビワモドキ科 Dillenia indica、カンラン科 Boswellia serrata、シナノキ科 Grewia salutaris、ミソハギ科 Woodfordia floribunda、マメ科 Cassia angustifolia、クワ科 Ficus ribes、アリノトウグサ科 Gunnera macrophylla、クワ科 Ficus religiosa、ヤシ科 Areca catechu、マメ科 Stryphlinodendron barbatiman、クワ科 Ficus bengalensis、ブナ科 Quercus brachystachys、マメ科 Acacia fornensia、マメ科 Cassia fistula、パンヤ科 Salmalia malabalica、フジウツギ科 Buddleja cordata、アカネ科 Uncaria gambir、アカネ科 Uncarina tomentosa、アカネ科 Capirona decorticans、ツツジ科 Lyonia ovalifolia、モクセイ科 Maytenus krukovii、トウダイグサ科 Phyllanthus niruri、ユリ科 Smilax aristolochiaefolia、ブナ科 Quercus mexicanaから選ばれる1種または2種以上の植物、またはこれらの溶媒抽出物を有効成分として含有することを特徴とするサイクリックAMP(cAMP)産生阻害剤である。
【0009】
【発明の実施の形態】
以下、本発明について詳述する。
本発明において用いられるシクンシ科 Terminalia chebula(別名:ミロバラン)、シクンシ科 Terminalia belerica(別名:セイタカミロバラン)、シソ科 Ocimum basillicum(別名:メボウキ、バジル,バジリコ)、ユキノシタ科 Bergenia ciliata、ウルシ科 Anacardium occidentale(別名:カシューナット)、ビワモドキ科 Dillenia indica(別名:ビワモドキ)、カンラン科 Boswellia serrata、シナノキ科 Grewia salutaris、ミソハギ科 Woodfordia floribunda、マメ科 Cassia angustifolia(別名:ホソバセンナ)、クワ科 Ficus ribes、アリノトウグサ科 Gunnera macrophylla、クワ科 Ficus religiosa(別名:インドボダイジュ、テンジクボダイジュ)、ヤシ科 Areca catechu(別名:ビンロウ)、マメ科 Stryphlinodendron barbatiman、クワ科 Ficus bengalensis(別名:ベンガルボダイジュ)、ブナ科 Quercus brachystachys、マメ科 Acacia fornensia、マメ科 Cassia fistula、パンヤ科 Salmalia malabalica(別名:キワタ、インドキワタノキ)、フジウツギ科 Buddleja cordata、 アカネ科 Uncaria gambir(別名:ガンビールノキ)、アカネ科 Uncarina tomentosa(別名:キャッツクロー)、アカネ科 Capirona decorticans、ツツジ科 Lyonia ovalifolia(別名:ネジキ)、モクセイ科 Maytenus krukovii、トウダイグサ科 Phyllanthus niruri(別名:キダチコミカンソウ)、ユリ科 Smilax aristolochiaefolia、ブナ科 Quercus mexicanaは、生のままでも乾燥したものでも使用することができるが、使用性、製剤化等の点から乾燥粉末あるいは溶媒抽出物として用いることが好ましい。
【0010】
それぞれの植物の好ましい使用部位は次の通りである。
即ち、シクンシ科 Terminalia chebula(別名:ミロバラン)については果実、シクンシ科 Terminalia belerica(別名:セイタカミロバラン)については果実、シソ科 Ocimum basillicum(別名:メボウキ、バジル,バジリコ)については種子、ユキノシタ科 Bergenia ciliataについては根茎、ウルシ科 Anacardium occidentale(別名:カシューナット)については樹皮、ビワモドキ科 Dillenia indica(別名:ビワモドキ)については樹皮、カンラン科 Boswellia serrataについては樹皮、シナノキ科 Grewia salutarisについては樹皮、ミソハギ科 Woodfordia floribundaについては葉または花、マメ科 Cassia angustifolia(別名:ホソバセンナ)については葉、クワ科 Ficus ribesについては果実、アリノトウグサ科 Gunnera macrophyllaについては種子、クワ科 Ficus religiosa(別名:インドボダイジュ、テンジクボダイジュ)については樹皮、ヤシ科ビンロウ属 Areca catechu(別名:ビンロウ)については種子、マメ科 Stryphlinodendron barbatimanについては樹皮、クワ科 Ficus bengalensis(別名:ベンガルボダイジュ)については樹皮、ブナ科 Quercus brachystachysについては幹、マメ科 Acacia fornensiaについては樹皮または樹脂、マメ科 Cassia fistulaについては樹皮、パンヤ科 Salmalia malabalica(別名:キワタ、インドキワタノキ)については花、フジウツギ科 Buddleja cordataについては葉、アカネ科 Uncaria gambir(別名:ガンビールノキ)については枝または樹皮、アカネ科 Uncarina tomentosa(別名:キャッツクロー)については樹皮、アカネ科 Capirona decorticansについては葉、ツツジ科 Lyonia ovalifolia(別名:ネジキ)については葉、モクセイ科 Maytenus krukoviiについては樹皮、トウダイグサ科 Phyllanthus niruri(別名:キダチコミカンソウ)については全草、ユリ科 Smilax aristolochiaefoliaについては枝、ブナ科 Quercus mexicanaについては木の芯を用いるのが好ましいが、他の部位を用いることもできる。
【0011】
上記各植物の溶媒抽出物は常法により得ることができ、例えば、抽出溶媒とともに浸漬または加熱還流した後、濾過し濃縮して得ることができる。抽出溶媒としては、通常抽出に用いられる溶媒であれば任意に用いることができ、例えば、水、メタノール、エタノール、プロピレングリコール、1,3−ブチレングリコール、グリセリン等のアルコール類、含水アルコール類、クロロホルム、ジクロルエタン、四塩化炭素、アセトン、酢酸エチル、ヘキサン等の有機溶媒類等を、それぞれ単独あるいは組み合わせて用いることができる。上記溶媒で抽出して得た抽出液をそのまま、あるいは濃縮したエキスを吸着法、例えばイオン交換樹脂あるいは活性炭を用いて不純物を除去あるいは脱色したものや、ポーラスポリマー(例えばアンバーライトXAD−2)のカラムにて吸着させた後、メタノールまたはエタノールで溶出し、濃縮したものも使用することができる。また分配法、例えば水/酢酸エチルで抽出した抽出物等も用いられる。
【0012】
このようにして得た上記植物抽出物は、安全性が高く、優れたサイクリックAMP(cAMP)産生阻害効果を有する。サイクリックAMP(cAMP)はプロテインキナーゼAを活性化させる作用があり、メラニン産生に関与するほか、アドレナリンやグルカゴン等の血糖上昇ホルモンによるグリコーゲンやホスホリラーゼの活性化作用や、心筋の弛緩及び平滑筋の収縮作用を媒介するなど、標的細胞内の特定酵素の生成や代謝調節に関与すると共に、物質輸送や分泌といった細胞の機能、細胞の増殖や分化などにも関与する物質である。
【0013】
上記植物抽出物をサイクリックAMP(cAMP)産生阻害剤として皮膚外用剤に配合して用いる場合、外用剤全量中に乾燥重量として0.000001〜5.0質量%配合するのが好ましく、より好ましくは0.00001〜3.0質量%、特に好ましくは0.00001〜1.0質量%である。
【0014】
上記植物抽出物を皮膚外用剤に配合して用いる場合、これら抽出物に加えて、本発明の効果を損なわない範囲内で、通常化粧品や医薬品等の皮膚外用剤に用いられる他の成分、例えば油分、湿潤剤、紫外線吸収剤、酸化防止剤、界面活性剤、防腐剤、保湿剤、香料、水、アルコール、増粘剤等を必要に応じて適宜配合することができる。
【0015】
前項の紫外線吸収剤としては、2−ヒドロキシ−4−メトキシベンゾフェノン、2−ヒドロキシ−4−メトキシベンゾフェノン−5−スルホン酸ナトリウム、ベンゾトリアゾリルブチルフェノールスルホン酸ナトリウム、メチレンビス−ベンゾトリアゾイルテトラメチルブチルフェノール等のベンゾフェノン誘導体、パラメトキシ桂皮酸オクチル、ジパラメトキシ桂皮酸モノ−2−エチルヘキサン酸グリセリル、イソペンチルトリメトキシ桂皮酸トリシロキサン等のメトキシ桂皮酸誘導体、ウロカニン酸、4−tert−4’−メトキシジベンゾイルメタン、ビス−エチルヘキシルオキシフェノールメトキシフェニルトリアジン、エチルヘキシルトリアゾン、フェニルベンジイミダゾールスルホン酸等を必要に応じて適宜配合することができる。
【0016】
さらに、エデト酸二ナトリウム、エデト酸三ナトリウム、クエン酸ナトリウム、ポリリン酸ナトリウム、メタリン酸ナトリウム、グルコン酸等の金属イオン封鎖剤、カフェイン、タンニン、ベラパミル、トラネキサム酸およびその誘導体、甘草抽出物、グラブリジン、各種生薬、酢酸トコフェロール、グリチルリチン酸およびその誘導体またはその塩等の薬剤、ビタミンC、アスコルビン酸リン酸マグネシウム、アスコルビン酸グルコシド、アルブチン、コウジ酸、レゾルシノール、エラグ酸、カミツレ抽出物等の他の美白剤、グルコース、フルクトース、マンノース、ショ糖、トレハロース等の糖類等も適宜配合することができる。
【0017】
また、本発明のサイクリックAMP(cAMP)産生阻害剤は、外皮に適用される化粧料、医薬品、医薬部外品等、特に好適には化粧料に広く適用することが可能であり、その剤型も、皮膚に適用できるものであればいずれでもよく、溶液系、可溶化系、乳化系、粉末分散系、水−油二層系、水−油−粉末三層系、軟膏、ゲル、エアゾール等、任意の剤型が適用される。
【0018】
また、本発明のサイクリックAMP(cAMP)産生阻害剤の使用形態も任意であり、例えば化粧水、乳液、クリーム、パック等のフェーシャル化粧料やファンデーションの他、メーキャップ化粧料、芳香化粧料、浴用剤等に用いることができる。
なお、上記の剤型および使用形態に本発明のサイクリックAMP(cAMP)産生阻害剤がとり得る形態が限定されるものではない。
【0019】
【実施例】
次に、実施例を挙げて本発明をさらに詳細に説明するが、本発明の技術的範囲はこれらの実施例によってなんら限定されるものでない。なお、配合量はすべて質量%である。
【0020】
実施例に先立ち、本発明の植物抽出物のサイクリックAMP(cAMP)産生阻害効果について、試験方法と評価方法について説明する。
【0021】
[試験方法および評価方法]
1.試料の調製
(1)Terminalia chebula 抽出物
Terminalia chebula の果実580gを、メタノールを2L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Terminalia chebula 抽出物195.3gを得た。
【0022】
(2)Terminalia belerica 抽出物
Terminalia belerica の果実619gを、メタノールを2L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Terminalia belerica 抽出物106.1gを得た。
【0023】
(3)Ocimum basillicum 抽出物
Ocimum basillicum の種子200gを、メタノールを1L用いて加温抽出し、抽出液を得た。この抽出液を濃縮し、Ocimum basillicum 抽出物8.4gを得た。
【0024】
(4)Bergenia ciliata 抽出物
Bergenia ciliata の根茎4600gを、メタノールを9L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Bergenia ciliata 抽出物331.7gを得た。
【0025】
(5)Anacardium occidentale 抽出物
Anacardium occidentale の樹皮200gを、メタノールを2L用いて加温抽出し、抽出液を得た。この抽出液を濃縮し、Anacardium occidentale 抽出物44.6gを得た。
【0026】
(6)Dillenia indica 抽出物
Dillenia indica の樹皮100gを、メタノールを0.5L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Dillenia indica 抽出物2.1gを得た。
【0027】
(7)Boswellia serrata 抽出物
Boswellia serrata の樹皮200gを、メタノールを1L用いて加温抽出し、抽出液を得た。この抽出液を濃縮し、Boswellia serrata 抽出物10.1gを得た。
【0028】
(8)Grewia salutaris 抽出物
Grewia salutaris の樹皮200gを、メタノールを2L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Grewia salutaris 抽出物2.2gを得た。
【0029】
(9)Woodfordia floribunda 抽出物
Woodfordia floribunda の葉200gを、メタノールを2L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Woodfordia floribunda 抽出物29.5gを得た。
【0030】
(10)Cassia angustifolia 抽出物
Cassia angustifolia の葉200gを、メタノールを2L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Cassia angustifolia 抽出物12.2gを得た。
【0031】
(11)Ficus ribes 抽出物
Ficus ribes の果実200gを、メタノールを1L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Ficus ribes 抽出物6.4gを得た。
【0032】
(12)Gunnera macrophylla 抽出物
Gunnera macrophylla の種子500gを、メタノールを7.5L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Gunnera macrophylla 抽出物93.0gを得た。
【0033】
(13)Ficus religiosa 抽出物
Ficus religiosa の樹皮200gを、メタノールを2L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Ficus religiosa 抽出物43.9gを得た。
【0034】
(14)Areca catechu 抽出物
Areca catechu の種子500gを、メタノールを7.5L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Areca catechu 抽出物26.7gを得た。
【0035】
(15)Stryphlinodendron barbatiman 抽出物
Stryphlinodendron barbatiman の樹皮500gを、メタノールを7.5L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Stryphlinodendron barbatiman 抽出物37.6gを得た。
【0036】
(16)Ficus bengalensis 抽出物
Ficus bengalensis の樹皮200gを、メタノールを2L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Ficus bengalensis 抽出物25.2gを得た。
【0037】
(17)Quercus brachystachys 抽出物
Quercus brachystachys の幹542gを、メタノールを1.5L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Quercus brachystachys 抽出物16.0gを得た。
【0038】
(18)Acacia fornensia 抽出物
Acacia fornensia の樹脂100gを、メタノールを1L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Acacia fornensia 抽出物29.7gを得た。
【0039】
(19)Cassia fistula 抽出物
Cassia fistula の樹皮500gを、メタノールを3L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Cassia fistula 抽出物77.0gを得た。
【0040】
(20)Salmalia malabalica 抽出物
Salmalia malabalica の花100gを、メタノールを2L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Salmalia malabalica 抽出物8.4gを得た。
【0041】
(21)Buddleja cordata 抽出物
Buddleja cordata の葉514gを、メタノールを3L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Buddleja cordata 抽出物47.3gを得た。
【0042】
(22)Uncaria gambir 抽出物
Uncaria gambir の枝500gを、メタノールを7.5L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Uncaria gambir 抽出物330.2gを得た。
【0043】
(23)Uncarina tomentosa 抽出物
Uncarina tomentosa の樹皮500gを、メタノールを7.5L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Uncarina tomentosa 抽出物12.5gを得た。
【0044】
(24)Capirona decorticans 抽出物
Capirona decorticans の葉500gを、メタノールを7.5L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Capirona decorticans 抽出物127.1gを得た。
【0045】
(25)Lyonia ovalifolia 抽出物
Lyonia ovalifolia の葉500gを、メタノールを3L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Lyonia ovalifolia 抽出物51.0gを得た。
【0046】
(26)Maytenus krukovii 抽出物
Maytenus krukovii の樹皮500gを、メタノールを7.5L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Maytenus krukovii 抽出物11.0gを得た。
【0047】
(27)Phyllanthus niruri 抽出物
Phyllanthus niruri の全草500gを、メタノールを7.5L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Phyllanthus niruri 抽出物27.3gを得た。
【0048】
(28)Smilax aristolochiaefolia 抽出物
Smilax aristolochiaefolia の枝552gを、メタノールを3L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Smilax aristolochiaefolia 抽出物45.8gを得た。
【0049】
(29)Quercus mexicana 抽出物
Quercus mexicana の木の芯529gを、メタノールを2.5L用いて室温抽出し、抽出液を得た。この抽出液を濃縮し、Quercus mexicana 抽出物64.7gを得た。
【0050】
上記各植物抽出物を70%エタノールに濃度2質量%となるよう溶解して、植物抽出物含有溶液とした。これら植物抽出物含有溶液を希釈して濃度を調整し、これを試料溶液として用い、以下の実験を行った。
【0051】
2.サイクリックAMP(cAMP)産生阻害効果測定
マウス由来のB16メラノーマ培養細胞を12ウェルプレートに播種し、10%FBSを含むダルベッコMEM培地でCOインキュベーター(95%空気、5%二酸化炭素)内、37℃の条件下で培養した。培養24時間後に培地を吸引し、メラノサイト刺激ホルモン(α―MSH、0.1nM)、および試料溶液を終濃度10−1〜10−3質量%(抽出乾燥物換算濃度)になるように添加した無血清培地を加えた。30分間インキュベート後、培地を除去し、TEバッファーにて細胞を集め、1.5mLマイクロチューブに移し、煮沸した後、この液中のサイクリックAMP(cAMP)量をサイクリックAMP(cAMP)測定キット(アマシャム社製)を用いて測定した。また、参考例として、バラ科(Rosaceae)バラ属(Rosa)に属するノバラ(Rosa canina L.)抽出物(エタノール抽出)についても、上記と同様の試験を行った。植物抽出物を添加していない試料(コントロール;70%エタノール)と比較し、下記判定基準により評価した。結果を表1に示す。
【0052】
(判定基準)
○:コントロールに比べサイクリックAMP(cAMP)産生阻害作用に優れる。
△:コントロールに比べサイクリックAMP(cAMP)産生阻害剤作用にやや優れる。
×:サイクリックAMP(cAMP)産生阻害作用なし。
【0053】
【表1】

Figure 2004359571
【0054】
以下に、種々の剤型の本発明によるサイクリックAMP(cAMP)産生阻害剤の配合例を、実施例として説明する。なお、植物抽出物の配合量は、乾燥残分量である。
【0055】
実施例1 バニシングクリーム
Figure 2004359571
(製法)
(15)に(4)、(6)〜(10)を加え、加熱して70℃に保った(水相)。一方、(1)〜(3)、(5)、(11)〜(14)を混合し、加熱融解して70℃に保った(油相)。水相に油相を加え予備乳化を行い、ホモミキサーで均一に乳化した後、よくかきまぜながら30℃まで冷却し、バニシングクリームを得た。
【0056】
実施例2 中性クリーム
Figure 2004359571
(製法)
(17)に(9)〜(12)、(16)を加え加熱して70℃に保った(水相)。一方、(1)〜(8)、(13)〜(15)を混合し、加熱融解して70℃に保った(油相)。水相に油相を加え予備乳化を行い、ホモミキサーで均一に乳化した後、よくかきまぜながら30℃まで冷却し、中性クリームを得た。
【0057】
実施例3 コールドクリーム
Figure 2004359571
(製法)
(13)に(8)、(10)、(11)および(12)を加え、加熱溶解して70℃に保った(水相)。一方、(1)〜(7)、(9)、(14)〜(17)を混合し、加熱融解して70℃に保った(油相)。水相に油相をかきまぜながら徐々の加え、反応を行った。反応終了後、ホモミキサーで均一に乳化し、乳化後よくかきまぜながら30℃まで冷却し、コールドクリームを得た。
【0058】
実施例4 栄養クリーム
Figure 2004359571
(製法)
(2)、(3)、(5)を50℃に昇温した後、(4)、(10)を加え完全に溶解した油相パーツに(1)を加えて均一に分散を行ったものに、(12)へ(6)、(7)、(8)、(11)を溶解させた水相パーツを50℃に加温して添加を行い、HMにて均一分散した後、室温まで冷却し、油中水型乳化組成物を得た。
【0059】
実施例5 乳液
Figure 2004359571
(製法)
(17)と(10)に、(16)および(7)を加温溶解し、さらに(6)、(8)、(9)、(11)〜(13)を溶解して、70℃に保った(水相)。一方、(1)〜(5)、(14)、(15)、(18)を混合し、加熱融解して70℃に保った(油相)。水相に油相を加え、予備乳化を行い、ホモミキサーで均一乳化し、乳化後、よくかきまぜながら30℃まで冷却し、乳液を得た。
【0060】
実施例6 乳液
Figure 2004359571
(製法)
(17)と(10)に、(16)および(7)を加温溶解し、さらに(6)、(8)、(9)、(11)〜(13)、(15)を溶解して、70℃に保った(水相)。一方、(1)〜(5)、(14)を混合し、加熱融解して70℃に保った(油相)。水相に油相を加え、予備乳化を行い、ホモミキサーで均一乳化し、乳化後、よくかきまぜながら30℃まで冷却し、乳液を得た。
【0061】
実施例7 乳液
Figure 2004359571
(製法)
(15)に(13)を加熱溶解し、さらに(14)、(5)〜(10)を溶解して、70℃に保った(水相)。一方、(1)〜(4)、および(11)、(12)を混合し、加熱融解して70℃に保った(油相)。水相に油相を加え、予備乳化を行い、ホモミキサーで均一に乳化し、乳化後、よくかきまぜながら30℃まで冷却し、乳液を得た。
【0062】
実施例8 乳液
Figure 2004359571
(製法)
(12)に(7)、(9)および(10)、(16)を加え、加熱溶解して70℃に保った(水相)。また、(6)に(11)を加えて溶解した(アルコール相)。一方、(1)〜(5)、(8)(13)、(14)、(15)を混合し、加熱融解して70℃に保った(油相)。水相に油相を加え予備乳化を行い、ホモミキサーで均一に乳化した。これをかきまぜながらアルコール相を加えた。その後かきまぜながら30℃まで冷却し、乳液を得た。
【0063】
実施例9 乳液
Figure 2004359571
(製法)
(17)と(9)に、(15)、(16)および(6)を溶解し、さらに(5)、(7)、(8)、(10)〜(12)、(14)を溶解して、70℃に保った(水相)。一方、(1)〜(4)および(13)、(18)を混合し、加熱融解して70℃に保った(油相)。水相に油相を加え、予備乳化を行い、ホモミキサーで均一乳化し、乳化後、よくかきまぜながら30℃まで冷却し、乳液を得た。
【0064】
実施例10 乳液
Figure 2004359571
(製法)
(16)に(9)、(11)〜(14)を加え、加熱して70℃に保った(水相)。一方、(1)〜(8)、(10)、(15)、(17)〜(20)を混合し、加熱溶解して70℃に保った(油相)。油相をかきまぜながら、この油相に水相を徐々に加え、ホモミキサーで均一に乳化した。乳化後、よくかきまぜながら30℃まで冷却し、乳液を得た。
【0065】
実施例11 乳液
Figure 2004359571
(製法)
(1)〜(8)を溶解し(油相)、(9)〜(16)を溶解し(水相)、油相に水相を添加し、乳化し、乳液を得た。
【0066】
実施例12 乳液
Figure 2004359571
(製法)
溶解した(B)相に、溶解した(A)相を添加し、乳化後、(C)相で中和し、乳液を得た。
【0067】
実施例13 ゼリー
Figure 2004359571
(製法)
(14)に(11)、(5)、(3)および(8)を均一に溶解した(水相)。一方、(1)に(2)、(4)、および(6)、(7)、(12)、(13)を溶解し、これを水相に添加した。次いで(9)、(10)で中和させ増粘して、ゼリーを得た。
【0068】
実施例14 ピールオフ型パック
Figure 2004359571
(製法)
80℃にて水相を調製し、50℃に冷却した。次いで室温で調製したアルコール相を添加後均一に混合し、放冷する。
【0069】
実施例15 粉末入りパック
Figure 2004359571
(製法)
室温にて水相を均一に調製した。ここに、室温にて調製したアルコール相を加し、均一に混合して粉末入りパックを得た。
【0070】
実施例16 吸水軟膏
Figure 2004359571
(製法)
(8)に(6)、(7)を加え、70℃に保った(水相)。一方、(1)〜(5)を70℃にて混合溶解した(油相)。水相に油相を添加し、ホモミキサーで均一に乳化後、冷却し、吸水軟膏を得た。
【0071】
実施例17 化粧水
Figure 2004359571
(製法)
水相およびアルコール相をそれぞれ均一溶解後、アルコール相を水相に添加し、均一に混合した。
【0072】
実施例18 化粧水
Figure 2004359571
(製法)
水相およびアルコール相をそれぞれ均一に溶解後、アルコール相を水相に添加し、均一に混合した。
【0073】
実施例19 バニシングクリーム
Figure 2004359571
(製法)
(15)に(4)、(6)〜(10)を加え、加熱して70℃に保った(水相)。一方、(1)〜(3)、(5)、(11)〜(14)を混合し、加熱融解して70℃に保った(油相)。水相に油相を加え予備乳化を行い、ホモミキサーで均一に乳化した後、よくかきまぜながら30℃まで冷却し、バニシングクリームを得た。
【0074】
実施例20 中性クリーム
Figure 2004359571
(製法)
(17)に(9)〜(12)、(16)を加え加熱して70℃に保った(水相)。一方、(1)〜(8)、(13)〜(15)を混合し、加熱融解して70℃に保った(油相)。水相に油相を加え予備乳化を行い、ホモミキサーで均一に乳化した後、よくかきまぜながら30℃まで冷却し、中性クリームを得た。
【0075】
実施例21 コールドクリーム
Figure 2004359571
(製法)
(13)に(8)、(10)、(11)および(12)を加え、加熱溶解して70℃に保った(水相)。一方、(1)〜(7)、(9)、(14)〜(17)を混合し、加熱融解して70℃に保った(油相)。水相に油相をかきまぜながら徐々の加え、反応を行った。反応終了後、ホモミキサーで均一に乳化し、乳化後よくかきまぜながら30℃まで冷却し、コールドクリームを得た。
【0076】
実施例22 栄養クリーム
Figure 2004359571
(製法)
(2)、(3)、(5)を50℃に昇温した後、(4)、(10)を加え完全に溶解した油相パーツに(1)を加えて均一に分散を行ったものに、(12)へ(6)、(7)、(8)、(11)を溶解させた水相パーツを50℃に加温して添加を行い、HMにて均一分散した後、室温まで冷却し、油中水型乳化組成物を得た。
【0077】
実施例23 乳液
Figure 2004359571
(製法)
(17)と(10)に、(16)および(7)を加温溶解し、さらに(6)、(8)、(9)、(11)〜(13)を溶解して、70℃に保った(水相)。一方、(1)〜(5)、(14)、(15)、(18)を混合し、加熱融解して70℃に保った(油相)。水相に油相を加え、予備乳化を行い、ホモミキサーで均一乳化し、乳化後、よくかきまぜながら30℃まで冷却し、乳液を得た。
【0078】
実施例24 乳液
Figure 2004359571
(製法)
(17)と(10)に、(16)および(7)を加温溶解し、さらに(6)、(8)、(9)、(11)〜(13)、(15)を溶解して、70℃に保った(水相)。一方、(1)〜(5)、(14)を混合し、加熱融解して70℃に保った(油相)。水相に油相を加え、予備乳化を行い、ホモミキサーで均一乳化し、乳化後、よくかきまぜながら30℃まで冷却し、乳液を得た。
【0079】
実施例25 乳液
Figure 2004359571
(製法)
(15)に(13)を加熱溶解し、さらに(14)、(5)〜(10)を溶解して、70℃に保った(水相)。一方、(1)〜(4)、および(11)、(12)を混合し、加熱融解して70℃に保った(油相)。水相に油相を加え、予備乳化を行い、ホモミキサーで均一に乳化し、乳化後、よくかきまぜながら30℃まで冷却し、乳液を得た。
【0080】
実施例26 乳液
Figure 2004359571
(製法)
(12)に(7)、(9)および(10)、(16)を加え、加熱溶解して70℃に保った(水相)。また、(6)に(11)を加えて溶解した(アルコール相)。一方、(1)〜(5)、(8)(13)、(14)、(15)を混合し、加熱融解して70℃に保った(油相)。水相に油相を加え予備乳化を行い、ホモミキサーで均一に乳化した。これをかきまぜながらアルコール相を加えた。その後かきまぜながら30℃まで冷却し、乳液を得た。
【0081】
実施例27 乳液
Figure 2004359571
(製法)
(16)に(9)、(11)〜(14)を加え、加熱して70℃に保った(水相)。一方、(1)〜(8)、(10)、(15)、(17)〜(20)を混合し、加熱溶解して70℃に保った(油相)。油相をかきまぜながら、この油相に水相を徐々に加え、ホモミキサーで均一に乳化した。乳化後、よくかきまぜながら30℃まで冷却し、乳液を得た。
【0082】
実施例28 乳液
Figure 2004359571
(製法)
(1)〜(8)を溶解し(油相)、(9)〜(16)を溶解し(水相)、油相に水相を添加し、乳化し、乳液を得た。
【0083】
実施例29 乳液
Figure 2004359571
(製法)
溶解した(B)相に、溶解した(A)相を添加し、乳化後、(C)相で中和し、乳液を得た。
【0084】
上記実施例1〜29のサイクリックAMP(cAMP)産生阻害剤はいずれもサイクリックAMP(cAMP)産生阻害効果試験において優れた効果が認められた。
【0085】
【発明の効果】
以上詳述したように、本発明によれば、優れたサイクリックAMP(cAMP)産生阻害効果を有する安全性の高いサイクリックAMP(cAMP)産生阻害剤が提供される。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a cyclic AMP (cAMP) production inhibitor containing a specific plant extract. The cyclic AMP (cAMP) production inhibitor of the present invention has an excellent cyclic AMP (cAMP) production inhibitory effect and is excellent in safety.
[0002]
[Prior art]
Pigmentation, such as skin spots and freckles, is caused by abnormal secretion of hormones, ultraviolet rays, inflammatory stimuli, etc., which activates the melanin production signaling pathway in epidermal pigment cells, and produces and expresses tyrosinase, the main enzyme of melanin production. Is caused by excessive deposition of melanin on the epidermis.
[0003]
As means for preventing such spots and freckles, substances that inhibit the activity of tyrosinase, which is a major enzyme for producing melanin, have been conventionally used. Specifically, topical application of creams and lotions containing kojic acid, ellagic acid, etc., whose mechanism of action is to capture copper ions essential for tyrosinase activity expression, and a structure similar to the substrate tyrosine A topical application of creams, lotions and the like, which contain a hydroquinone derivative, a resorcinol derivative, etc., which acts as a tyrosinase competition inhibitor, or a substance having an action mechanism other than the above, dopaquinone which is a melanin precursor The administration of L-ascorbic acid has been carried out with the mechanism of suppressing melanin production by reducing to Dopa.
[0004]
The above substances act on the produced tyrosinase or on dopaquinone produced by expressing the tyrosinase activity, and do not inhibit the tyrosinase production itself. Therefore, there was a disadvantage that the effect itself and its persistence were weak. In addition, L-ascorbic acid has poor stability in the drug substance and the base, and a large amount of L-ascorbic acid is required to obtain an effect of sufficiently preventing spots and freckles.
[0005]
In recent years, various active ingredients contained in plant extracts have been receiving attention. Various actions such as an antitumor action, including an antioxidant action of polyphenols contained in many plants, have been reported. A variety of plant extracts having a whitening effect have been searched for.
As a plant having a whitening effect, conventionally, Sakurako, Yomi, Jiyu, Sakinoshita, and the like, these plant extracts also have a mechanism of action that inhibits tyrosinase activity, The whitening effect and its persistence were not satisfactory.
On the other hand, as substances that act on the signal transduction pathway and inhibit melanin production itself, syrup having a nitric oxide pathway inhibiting action, chamomile having a protein kinase C pathway inhibiting action, and the like have been reported. However, these transmission pathways have a low involvement in melanin production, and it is difficult to obtain remarkable inhibition of melanin production. Therefore, development of better plant extract medicinal agents has been expected.
The present applicant has already found that the rose of the family Rosaceae has a whitening effect by inhibiting the production of cyclic AMP (cAMP) (for example, see Patent Document 1).
[0006]
[Patent Document 1]
JP-A-2002-29959 (paragraphs [0021] to [0038])
[0007]
[Problems to be solved by the invention]
The present inventors have conducted intensive studies in view of the above circumstances, and as a result, have found that specific plants and extracts thereof have a high adenylate cyclase pathway inhibitory effect, which is highly involved in melanin production, and complete the present invention. Reached.
[0008]
[Means for Solving the Problems]
That is, the present invention is combretaceae Terminalia chebula, combretaceae Terminalia Belerica, Labiatae Ocimum Basillicum, Saxifragaceae Bergenia ciliata, Anacardiaceae Anacardium occidentale, dilleniaceae Dillenia indica, Burseraceae Boswellia serrata, Tiliaceae Grewia salutaris, Lythraceae Woodfordia floribunda, Leguminosae Cassia angustifolia, Mulberry Ficus ribes, Arinocephaea Gunnera macrophylla, Mulberry Ficus religiosa, Palmaceae Areca catechu, Legume Stryphrin dendron barbatiman, Moraceae Ficus bengalensis, Fagaceae Quercus brachystachys, legume Acacia fornensia, legumes Cassia fistula, bombacaceae Salmalia malabalica, Fujiutsugi Department of Buddleja cordata, Rubiaceae Uncaria gambir, Rubiaceae Uncarina tomentosa, Rubiaceae Capirona decorticans, Ericaceae Lyonia ovalifolia, Lentinaceae Maytenus krukovii, Euphorbiaceae Phyllanthus niruri, Lily Smilux aristolochiaefolia, Fagaceae Quercus mexicana Is one or more plants or cyclic AMP (cAMP) production inhibitor characterized by containing these solvents extract as an active ingredient, barrel.
[0009]
BEST MODE FOR CARRYING OUT THE INVENTION
Hereinafter, the present invention will be described in detail.
Terminaria chebula (alias: mirobaran), terminaceae Terminaria belerica (alias: Seika mirobalan), Lamiaceae Ocimum basilicum (alias: Mebuki, basil, basilicoceae) (Alias: cashew nut), loquatiaceae Dillenia indica (alias: loquatia), lanternaceae Boswellia serrata, lindenaceae Grewia salutaris, scorpionaceae family: Woodfordia floridae, sect. s, Arino spurge family Gunnera macrophylla, mulberry family Ficus religiosa (alias: Indian bodied, stag beetle), coconut palm Areca catechu (alias: betel wax), legume family Stryphrinda genba, var. Brachystachys, legumes Acacia fornensia, legumes Cassia fistula, panicaceae Salmaria malabalica (alias: Kiwata, Indian crocodile), Phyllodaceae Buddleja acnae, Ubiaceae abb. omentosa (also known as cat's claw), Rubiaceae Capirona decorticans, azalea family Lyonia ovalifolia (aka: threading), Oleaceae Maytenus krukovii, Euphorbiaceae Phyllanthus niruri (aka: frutescens Phyllanthus urinaria), Liliaceae Smilax aristolochiaefolia, Fagaceae Quercus mexicana is, Raw or dried products can be used, but it is preferable to use them as dry powders or solvent extracts from the viewpoints of usability, formulation and the like.
[0010]
Preferred sites of use for each plant are as follows.
That is, for the beetle family Terminaria chebula (also called milobalane), fruits, for the beetle family Terminaria belerica (also called Seika mirobalan), fruits, and for the Labiatae family Ocimum basilicum (also known as Mebuki, basil, and basilicog), seeds are used. Rhizome for Ciliata, Bark for Anacardium occidentale (Also known as Cashew Nut), Bark for Dilenia indica (Alternative name: Biwamodoki), Bark for Citridaceae, Bark for Botanaceae Boswellia serrata, and Barkaceae for the genus Boswellia serrata, Woodfordia floribunda For leaves and flowers, for the legume Cassia angustifolia (alias: Hosovasenna), leaves, for the mulberry family, Ficus ribes, fruits; for the Arinocephalidaceae Gunnera macrophylla, seeds; for the mulberry family, Ficus religiosa (alias: Aceridae) Acacatechu (Acacia catechu) is a seed for the betel wax, a bark for the leguminous Stryphlinodendron barbataman, a bark for the mulberry family Ficus bengalensis (also known as the bengalbodaiju), and a barnaceae for the family Quericaena for the family Beechacea. About the bark or Fats, Legumes Cassia fistula is a bark, Panaceae Salmaria malabalica (alias: Kiwata, Indian crocodile) is a flower, Buddleja Buddleja cordata is a leaf, Rubiaceae is a tree of the family Rubiaceae, and Uncaria is a gambir tree. Rubiaceae Uncarina tomentosa (also known as cats claw) is bark, Rubiaceae Capirona decorticans is a leaf, ericaceae Lyonia ovalifolia (also known as Nejiki) is a leaf, and Oleaceae Maytenus rikusa is a member of the family Phytaceae. About whole plant, lily family S Branch for ilax aristolochiaefolia, it is preferred to use a core of wood for Fagaceae Quercus mexicana, may use other sites.
[0011]
The solvent extract of each of the above plants can be obtained by a conventional method. For example, it can be obtained by immersing or heating under reflux with an extraction solvent, followed by filtration and concentration. As the extraction solvent, any solvent can be used as long as it is a solvent usually used for extraction. For example, water, methanol, ethanol, propylene glycol, 1,3-butylene glycol, alcohols such as glycerin, hydrous alcohols, chloroform And organic solvents such as dichloroethane, carbon tetrachloride, acetone, ethyl acetate and hexane, etc., can be used alone or in combination. The extract obtained by extraction with the above-mentioned solvent is used as it is, or a concentrated extract is subjected to an adsorption method, for example, a substance obtained by removing or decoloring impurities using an ion exchange resin or activated carbon, or a porous polymer (eg, Amberlite XAD-2). After adsorption by a column, elution with methanol or ethanol and concentration can also be used. In addition, a partitioning method, for example, an extract extracted with water / ethyl acetate and the like are also used.
[0012]
The plant extract thus obtained is highly safe and has an excellent cyclic AMP (cAMP) production inhibitory effect. Cyclic AMP (cAMP) has an action of activating protein kinase A, and is involved in melanin production. In addition, it activates glycogen and phosphorylase by blood glucose-elevating hormones such as adrenaline and glucagon, and relaxes the heart muscle and smooth muscle. It is a substance that mediates contractile action and is involved in the production and metabolic regulation of specific enzymes in target cells, and is also involved in cell functions such as substance transport and secretion, cell proliferation and differentiation, and the like.
[0013]
When the plant extract is used as a cyclic AMP (cAMP) production inhibitor in an external preparation for skin, it is preferably used in an amount of 0.000001 to 5.0% by mass as a dry weight in the total amount of the external preparation, and more preferably. Is 0.00001 to 3.0% by mass, particularly preferably 0.00001 to 1.0% by mass.
[0014]
When the plant extract is used in combination with a skin external preparation, in addition to these extracts, within the range not impairing the effects of the present invention, other components usually used in skin external preparations such as cosmetics and pharmaceuticals, for example, An oil, a wetting agent, an ultraviolet absorber, an antioxidant, a surfactant, a preservative, a humectant, a fragrance, water, alcohol, a thickener, and the like can be appropriately compounded as necessary.
[0015]
Examples of the ultraviolet absorbent described in the preceding paragraph include 2-hydroxy-4-methoxybenzophenone, sodium 2-hydroxy-4-methoxybenzophenone-5-sulfonate, sodium benzotriazolylbutylphenolsulfonate, and methylenebis-benzotriazoyltetramethylbutylphenol. Benzophenone derivatives, octyl paramethoxycinnamate, glyceryl mono-2-ethylhexanoate diparamethoxycinnamate, methoxycinnamic acid derivatives such as isopentyltrimethoxycinnamate trisiloxane, urocanic acid, 4-tert-4'-methoxydibenzoylmethane , Bis-ethylhexyloxyphenol methoxyphenyl triazine, ethylhexyl triazone, phenylbenzimidazole sulfonic acid and the like can be appropriately compounded as necessary. .
[0016]
Furthermore, disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, sequestering agents such as gluconic acid, caffeine, tannin, verapamil, tranexamic acid and its derivatives, licorice extract, Other drugs such as grabradine, various crude drugs, tocopherol acetate, glycyrrhizic acid and derivatives or salts thereof, vitamin C, magnesium ascorbate phosphate, glucoside ascorbate, arbutin, kojic acid, resorcinol, ellagic acid, chamomile extract, etc. Whitening agents, sugars such as glucose, fructose, mannose, sucrose, trehalose and the like can also be appropriately blended.
[0017]
In addition, the cyclic AMP (cAMP) production inhibitor of the present invention can be widely applied to cosmetics, pharmaceuticals, quasi-drugs and the like, particularly preferably applied to cosmetics, which are applied to the outer skin. The mold may be any as long as it can be applied to the skin, and may be a solution system, a solubilizing system, an emulsifying system, a powder dispersing system, a water-oil two-layer system, a water-oil-powder three-layer system, an ointment, a gel, or an aerosol. Any dosage form is applied.
[0018]
The form of use of the cyclic AMP (cAMP) production inhibitor of the present invention is also optional. For example, in addition to facial cosmetics and foundations such as lotions, emulsions, creams, and packs, makeup cosmetics, aromatic cosmetics, and baths Agent and the like.
The form that the cyclic AMP (cAMP) production inhibitor of the present invention can take is not limited to the above dosage form and use form.
[0019]
【Example】
Next, the present invention will be described in more detail with reference to examples, but the technical scope of the present invention is not limited by these examples. In addition, all compounding amounts are mass%.
[0020]
Prior to the examples, test methods and evaluation methods for the cyclic AMP (cAMP) production inhibitory effect of the plant extract of the present invention will be described.
[0021]
[Test method and evaluation method]
1. Preparation of Sample (1) Extract of Terminalia chebula Extract 580 g of fruit of Terminalia chebula was extracted at room temperature with 2 L of methanol to obtain an extract. This extract was concentrated to obtain 195.3 g of a Terminaria chebula extract.
[0022]
(2) Terminaria belerica extract 619 g of Fruit of Terminaria belerica was extracted at room temperature with 2 L of methanol to obtain an extract. This extract was concentrated to obtain 106.1 g of a Terminaria belerica extract.
[0023]
(3) Ocimum basilicum extract 200 g of Ocimum basilicum seeds were warm-extracted with 1 L of methanol to obtain an extract. The extract was concentrated to obtain 8.4 g of Ocimum basilicum extract.
[0024]
(4) Bergenia ciliata extract 4600 g of Rhizome of Bergenia ciliata was extracted at room temperature with 9 L of methanol to obtain an extract. The extract was concentrated to obtain 331.7 g of a Bergenia cliata extract.
[0025]
(5) Anacardium occidentale extract 200 g of bark of Anacardium occidentale was warm-extracted with 2 L of methanol to obtain an extract. This extract was concentrated to obtain 44.6 g of Anacardium occipentale extract.
[0026]
(6) Dillenia indica extract 100 g of Dillenia indica bark was extracted at room temperature with 0.5 L of methanol to obtain an extract. This extract was concentrated to obtain 2.1 g of Dillenia indica extract.
[0027]
(7) Boswellia serrata extract 200 g of bark of Boswellia serrata was warm-extracted with 1 L of methanol to obtain an extract. The extract was concentrated to obtain 10.1 g of Boswellia serrata extract.
[0028]
(8) Grevia salutaris extract 200 g of the bark of Grevia salutaris was extracted at room temperature with 2 L of methanol to obtain an extract. The extract was concentrated to obtain 2.2 g of Grevia salutaris extract.
[0029]
(9) Woodfordia floribunda extract 200 g of Woodfordia floribunda leaves were extracted at room temperature with 2 L of methanol to obtain an extract. The extract was concentrated to obtain 29.5 g of Woodfordia floribunda extract.
[0030]
(10) Cassia angustifolia extract 200 g of Cassia angustifolia leaves were extracted at room temperature with 2 L of methanol to obtain an extract. This extract was concentrated to obtain 12.2 g of Cassia angustifolia extract.
[0031]
(11) Ficus ribes extract 200 g of fruit of Ficus ribes was extracted at room temperature with 1 L of methanol to obtain an extract. The extract was concentrated to obtain 6.4 g of a Ficus ribes extract.
[0032]
(12) Gunnera macrophylla extract 500 g of seeds of Gunnera macrophylla extract were extracted at room temperature using 7.5 L of methanol to obtain an extract. The extract was concentrated to obtain 93.0 g of Gunnera macrophylla extract.
[0033]
(13) Ficus religiosa extract 200 g of bark of Ficus religiosa extract was extracted at room temperature with 2 L of methanol to obtain an extract. This extract was concentrated to obtain 43.9 g of a Ficus religiosa extract.
[0034]
(14) Areca catech extract 500 g of Aca catech seeds were extracted at room temperature with 7.5 L of methanol to obtain an extract. The extract was concentrated to obtain 26.7 g of an Areca catechu extract.
[0035]
(15) Stryphlinodendron barbatiman Extract 500 g of bark of the extract, Stryphlinodendron barbatiman, was extracted at room temperature with 7.5 L of methanol to obtain an extract. This extract was concentrated to obtain 37.6 g of a Stryphlinodendron barbatiman extract.
[0036]
(16) Ficus bengalensis extract 200 g of bark of Ficus bengalensis extract was extracted at room temperature with 2 L of methanol to obtain an extract. This extract was concentrated to obtain 25.2 g of a Ficus bengalensis extract.
[0037]
(17) Quercus brachystachys extract 542 g of the stem of Quercus brachystachys was extracted at room temperature with 1.5 L of methanol to obtain an extract. This extract was concentrated to obtain 16.0 g of Quercus brachystachys extract.
[0038]
(18) Acacia fornensia extract 100 g of Acacia fornensia resin was extracted at room temperature with 1 L of methanol to obtain an extract. The extract was concentrated to obtain 29.7 g of Acacia fornensia extract.
[0039]
(19) Cassia fistula extract 500 g of bark of Cassia fistula was extracted at room temperature with 3 L of methanol to obtain an extract. The extract was concentrated to obtain 77.0 g of Cassia fistula extract.
[0040]
(20) Salmalia malabalica extract 100 g of Salmalia malabalica flowers were extracted at room temperature with 2 L of methanol to obtain an extract. The extract was concentrated to obtain 8.4 g of a Salmalia malabalica extract.
[0041]
(21) Buddleja corddata extract 514 g of leaves of Buddleja corddata were extracted at room temperature with 3 L of methanol to obtain an extract. The extract was concentrated to obtain 47.3 g of Buddleja corddata extract.
[0042]
(22) Uncaria gambir extract 500 g of branches of Uncaria gambir were extracted at room temperature with 7.5 L of methanol to obtain an extract. The extract was concentrated to obtain 330.2 g of Uncaria gambir extract.
[0043]
(23) Uncarina tomentosa extract 500 g of bark of Uncarina tomentosa was extracted with 7.5 L of methanol at room temperature to obtain an extract. The extract was concentrated to obtain 12.5 g of Uncarina tomentosa extract.
[0044]
(24) Capirona decorticans extract 500 g of Capirona decorticans leaves were extracted at room temperature with 7.5 L of methanol to obtain an extract. This extract was concentrated to obtain 127.1 g of an extract of Capirona decorticans.
[0045]
(25) Lyonia ovalifolia extract 500 g of leaves of Lyonia ovalifolia were extracted at room temperature with 3 L of methanol to obtain an extract. The extract was concentrated to obtain 51.0 g of Lyonia ovalifolia extract.
[0046]
(26) Maytenus krukovii extract 500 g of the bark of the Maytenus krukovii extract was extracted at room temperature with 7.5 L of methanol to obtain an extract. The extract was concentrated to obtain 11.0 g of Maytenus krukovii extract.
[0047]
(27) Phyllanthus niruri extract 500 g of whole plant of Phyllanthus niruri was extracted at room temperature with 7.5 L of methanol to obtain an extract. The extract was concentrated to obtain 27.3 g of a Phyllanthus niruri extract.
[0048]
(28) Smilax aristolochiaefolia Extract 552 g of the branch of Smilax aristolochiaefolia was extracted at room temperature with 3 L of methanol to obtain an extract. This extract was concentrated to obtain 45.8 g of a Smilax aristolochia efolia extract.
[0049]
(29) Quercus mexicana extract 529 g of Quercus mexicana tree core was extracted at room temperature with 2.5 L of methanol to obtain an extract. The extract was concentrated to obtain 64.7 g of Quercus mexicana extract.
[0050]
Each of the above plant extracts was dissolved in 70% ethanol to a concentration of 2% by mass to obtain a plant extract-containing solution. The concentration of the plant extract-containing solution was adjusted by diluting the solution, and this was used as a sample solution, and the following experiment was performed.
[0051]
2. Cyclic AMP (cAMP) production inhibitory effect measurement B16 melanoma cultured cells derived from mice were seeded in a 12-well plate, and in a CO 2 incubator (95% air, 5% carbon dioxide) in Dulbecco's MEM medium containing 10% FBS, 37%. The culture was performed under the condition of ° C. After culture for 24 hours, the medium was aspirated, and melanocyte stimulating hormone (α-MSH, 0.1 nM) and a sample solution were added to a final concentration of 10 −1 to 10 −3 mass% (concentration in terms of dry extract). Serum-free medium was added. After incubating for 30 minutes, the medium was removed, the cells were collected with TE buffer, transferred to a 1.5 mL microtube, boiled, and the amount of cyclic AMP (cAMP) in this solution was measured using a cyclic AMP (cAMP) measurement kit. (Manufactured by Amersham). In addition, as a reference example, a test similar to the above was performed on an extract of rose (Rosa canina L.) belonging to the genus Rosaceae (Rosa), which was extracted with ethanol. It was compared with a sample to which no plant extract was added (control; 70% ethanol) and evaluated according to the following criteria. Table 1 shows the results.
[0052]
(Judgment criteria)
:: Excellent in cyclic AMP (cAMP) production inhibitory effect as compared with control.
Δ: Slightly superior to cyclic AMP (cAMP) production inhibitor action as compared to control.
×: No cyclic AMP (cAMP) production inhibitory action.
[0053]
[Table 1]
Figure 2004359571
[0054]
Examples of the formulation of the cyclic AMP (cAMP) production inhibitor according to the present invention in various dosage forms are described below as examples. In addition, the compounding quantity of a plant extract is a dry residue amount.
[0055]
Example 1 Burnishing cream
Figure 2004359571
(Production method)
(4) and (6) to (10) were added to (15), and the mixture was heated and maintained at 70 ° C. (aqueous phase). On the other hand, (1) to (3), (5), (11) to (14) were mixed, melted by heating, and kept at 70 ° C. (oil phase). The oil phase was added to the water phase to carry out preliminary emulsification, and after uniform emulsification with a homomixer, the mixture was cooled to 30 ° C. while stirring well to obtain a burnishing cream.
[0056]
Example 2 Neutral cream
Figure 2004359571
(Production method)
(17), (9) to (12) and (16) were added, and the mixture was heated and maintained at 70 ° C. (aqueous phase). On the other hand, (1) to (8) and (13) to (15) were mixed, melted by heating, and kept at 70 ° C. (oil phase). The oil phase was added to the water phase to carry out preliminary emulsification, and after uniform emulsification with a homomixer, the mixture was cooled to 30 ° C. while stirring well to obtain a neutral cream.
[0057]
Example 3 Cold cream
Figure 2004359571
(Production method)
(8), (10), (11) and (12) were added to (13), and the mixture was dissolved by heating and kept at 70 ° C. (aqueous phase). On the other hand, (1) to (7), (9) and (14) to (17) were mixed, melted by heating, and kept at 70 ° C. (oil phase). The reaction was carried out by gradually adding the oil phase to the aqueous phase while stirring. After completion of the reaction, the mixture was uniformly emulsified with a homomixer, cooled to 30 ° C. while stirring well after emulsification, and a cold cream was obtained.
[0058]
Example 4 Nutrition cream
Figure 2004359571
(Production method)
After heating (2), (3) and (5) to 50 ° C, (4) and (10) were added, and (1) was added to the completely dissolved oil phase parts to perform uniform dispersion. Then, the aqueous phase parts in which (6), (7), (8), and (11) are dissolved are added to (12) by heating to 50 ° C., uniformly dispersed with HM, and then to room temperature. After cooling, a water-in-oil emulsion composition was obtained.
[0059]
Example 5 Emulsion
Figure 2004359571
(Production method)
(16) and (7) are dissolved by heating in (17) and (10), and (6), (8), (9) and (11) to (13) are further dissolved. Kept (aqueous phase). On the other hand, (1) to (5), (14), (15), and (18) were mixed, melted by heating, and kept at 70 ° C. (oil phase). The oil phase was added to the aqueous phase, preliminarily emulsified, uniformly emulsified with a homomixer, and after emulsification, cooled to 30 ° C. while stirring well to obtain an emulsion.
[0060]
Example 6 Emulsion
Figure 2004359571
(Production method)
(16) and (7) are dissolved by heating in (17) and (10), and (6), (8), (9), (11) to (13) and (15) are further dissolved. , 70 ° C (aqueous phase). On the other hand, (1) to (5) and (14) were mixed, heated and melted, and kept at 70 ° C. (oil phase). The oil phase was added to the aqueous phase, preliminarily emulsified, uniformly emulsified with a homomixer, and after emulsification, cooled to 30 ° C. while stirring well to obtain an emulsion.
[0061]
Example 7 Emulsion
Figure 2004359571
(Production method)
(13) was dissolved in (15) by heating, and (14) and (5) to (10) were further dissolved and kept at 70 ° C. (aqueous phase). On the other hand, (1) to (4), and (11) and (12) were mixed, heated and melted, and kept at 70 ° C (oil phase). The oil phase was added to the water phase, preliminarily emulsified, uniformly emulsified with a homomixer, and after emulsification, cooled to 30 ° C. while stirring well to obtain an emulsion.
[0062]
Example 8 Emulsion
Figure 2004359571
(Production method)
(7), (9) and (10) and (16) were added to (12), and the mixture was dissolved by heating and maintained at 70 ° C. (aqueous phase). Further, (11) was added to (6) and dissolved (alcohol phase). On the other hand, (1) to (5), (8), (13), (14), and (15) were mixed, melted by heating, and kept at 70 ° C. (oil phase). The oil phase was added to the water phase to perform preliminary emulsification, and the mixture was uniformly emulsified with a homomixer. The alcohol phase was added while stirring this. Thereafter, the mixture was cooled to 30 ° C. while stirring to obtain an emulsion.
[0063]
Example 9 Emulsion
Figure 2004359571
(Production method)
Dissolve (15), (16) and (6) in (17) and (9) and further dissolve (5), (7), (8), (10)-(12) and (14) And maintained at 70 ° C. (aqueous phase). On the other hand, (1) to (4) and (13) and (18) were mixed, heated and melted, and kept at 70 ° C. (oil phase). The oil phase was added to the aqueous phase, preliminarily emulsified, uniformly emulsified with a homomixer, and after emulsification, cooled to 30 ° C. while stirring well to obtain an emulsion.
[0064]
Example 10 Emulsion
Figure 2004359571
(Production method)
(9) and (11) to (14) were added to (16), and the mixture was heated and maintained at 70 ° C (aqueous phase). On the other hand, (1) to (8), (10), (15), (17) to (20) were mixed, dissolved by heating, and kept at 70 ° C. (oil phase). While stirring the oil phase, the water phase was gradually added to the oil phase, and the mixture was uniformly emulsified with a homomixer. After emulsification, the mixture was cooled to 30 ° C. while stirring well to obtain an emulsion.
[0065]
Example 11 Emulsion
Figure 2004359571
(Production method)
(1) to (8) were dissolved (oil phase), (9) to (16) were dissolved (aqueous phase), and the aqueous phase was added to the oil phase and emulsified to obtain an emulsion.
[0066]
Example 12 Emulsion
Figure 2004359571
(Production method)
The dissolved (A) phase was added to the dissolved (B) phase, emulsified, and then neutralized with the (C) phase to obtain an emulsion.
[0067]
Example 13 Jelly
Figure 2004359571
(Production method)
(11), (5), (3) and (8) were uniformly dissolved in (14) (aqueous phase). On the other hand, (2), (4), and (6), (7), (12), and (13) were dissolved in (1), and this was added to the aqueous phase. Next, the mixture was neutralized and thickened by (9) and (10) to obtain jelly.
[0068]
Example 14 Peel-off type pack
Figure 2004359571
(Production method)
An aqueous phase was prepared at 80 ° C and cooled to 50 ° C. Next, the alcohol phase prepared at room temperature is added, mixed uniformly, and left to cool.
[0069]
Example 15 Pack with powder
Figure 2004359571
(Production method)
The aqueous phase was uniformly prepared at room temperature. Here, the alcohol phase prepared at room temperature was added and mixed uniformly to obtain a powder-containing pack.
[0070]
Example 16 Water Absorbing Ointment
Figure 2004359571
(Production method)
(6) and (7) were added to (8), and the mixture was maintained at 70 ° C. (aqueous phase). On the other hand, (1) to (5) were mixed and dissolved at 70 ° C. (oil phase). The oil phase was added to the water phase, uniformly emulsified with a homomixer, and then cooled to obtain a water-absorbing ointment.
[0071]
Example 17 Lotion
Figure 2004359571
(Production method)
After uniformly dissolving the aqueous phase and the alcohol phase, the alcohol phase was added to the aqueous phase and mixed uniformly.
[0072]
Example 18 Lotion
Figure 2004359571
(Production method)
After uniformly dissolving the aqueous phase and the alcohol phase, the alcohol phase was added to the aqueous phase and mixed uniformly.
[0073]
Example 19 Burnishing cream
Figure 2004359571
(Production method)
(4) and (6) to (10) were added to (15), and the mixture was heated and maintained at 70 ° C. (aqueous phase). On the other hand, (1) to (3), (5), (11) to (14) were mixed, melted by heating, and kept at 70 ° C. (oil phase). The oil phase was added to the water phase to carry out preliminary emulsification, and after uniform emulsification with a homomixer, the mixture was cooled to 30 ° C. while stirring well to obtain a burnishing cream.
[0074]
Example 20 Neutral cream
Figure 2004359571
(Production method)
(17), (9) to (12) and (16) were added, and the mixture was heated and maintained at 70 ° C. (aqueous phase). On the other hand, (1) to (8) and (13) to (15) were mixed, melted by heating, and kept at 70 ° C. (oil phase). The oil phase was added to the water phase to carry out preliminary emulsification, and after uniform emulsification with a homomixer, the mixture was cooled to 30 ° C. while stirring well to obtain a neutral cream.
[0075]
Example 21 Cold cream
Figure 2004359571
(Production method)
(8), (10), (11) and (12) were added to (13), and the mixture was dissolved by heating and kept at 70 ° C. (aqueous phase). On the other hand, (1) to (7), (9) and (14) to (17) were mixed, melted by heating, and kept at 70 ° C. (oil phase). The reaction was carried out by gradually adding the oil phase to the aqueous phase while stirring. After completion of the reaction, the mixture was uniformly emulsified with a homomixer, cooled to 30 ° C. while stirring well after emulsification, and a cold cream was obtained.
[0076]
Example 22 Nourishing cream
Figure 2004359571
(Production method)
After heating (2), (3) and (5) to 50 ° C, (4) and (10) were added, and (1) was added to the completely dissolved oil phase parts to perform uniform dispersion. Then, the aqueous phase parts in which (6), (7), (8), and (11) are dissolved are added to (12) by heating to 50 ° C., uniformly dispersed with HM, and then to room temperature. After cooling, a water-in-oil emulsion composition was obtained.
[0077]
Example 23 Emulsion
Figure 2004359571
(Production method)
(16) and (7) are dissolved by heating in (17) and (10), and (6), (8), (9) and (11) to (13) are further dissolved. Kept (aqueous phase). On the other hand, (1) to (5), (14), (15), and (18) were mixed, melted by heating, and kept at 70 ° C. (oil phase). The oil phase was added to the aqueous phase, preliminarily emulsified, uniformly emulsified with a homomixer, and after emulsification, cooled to 30 ° C. while stirring well to obtain an emulsion.
[0078]
Example 24 Emulsion
Figure 2004359571
(Production method)
(16) and (7) are dissolved by heating in (17) and (10), and (6), (8), (9), (11) to (13) and (15) are further dissolved. , 70 ° C (aqueous phase). On the other hand, (1) to (5) and (14) were mixed, heated and melted, and kept at 70 ° C. (oil phase). The oil phase was added to the aqueous phase, preliminarily emulsified, uniformly emulsified with a homomixer, and after emulsification, cooled to 30 ° C. while stirring well to obtain an emulsion.
[0079]
Example 25 Emulsion
Figure 2004359571
(Production method)
(13) was dissolved in (15) by heating, and (14) and (5) to (10) were further dissolved and kept at 70 ° C. (aqueous phase). On the other hand, (1) to (4), and (11) and (12) were mixed, heated and melted, and kept at 70 ° C (oil phase). The oil phase was added to the water phase, preliminarily emulsified, uniformly emulsified with a homomixer, and after emulsification, cooled to 30 ° C. while stirring well to obtain an emulsion.
[0080]
Example 26 Emulsion
Figure 2004359571
(Production method)
(7), (9) and (10) and (16) were added to (12), and the mixture was dissolved by heating and maintained at 70 ° C. (aqueous phase). Further, (11) was added to (6) and dissolved (alcohol phase). On the other hand, (1) to (5), (8), (13), (14), and (15) were mixed, melted by heating, and kept at 70 ° C. (oil phase). The oil phase was added to the water phase to perform preliminary emulsification, and the mixture was uniformly emulsified with a homomixer. The alcohol phase was added while stirring this. Thereafter, the mixture was cooled to 30 ° C. while stirring to obtain an emulsion.
[0081]
Example 27 Emulsion
Figure 2004359571
(Production method)
(9) and (11) to (14) were added to (16), and the mixture was heated and maintained at 70 ° C (aqueous phase). On the other hand, (1) to (8), (10), (15), (17) to (20) were mixed, dissolved by heating, and kept at 70 ° C. (oil phase). While stirring the oil phase, the water phase was gradually added to the oil phase, and the mixture was uniformly emulsified with a homomixer. After emulsification, the mixture was cooled to 30 ° C. while stirring well to obtain an emulsion.
[0082]
Example 28 Emulsion
Figure 2004359571
(Production method)
(1) to (8) were dissolved (oil phase), (9) to (16) were dissolved (aqueous phase), and the aqueous phase was added to the oil phase and emulsified to obtain an emulsion.
[0083]
Example 29 Emulsion
Figure 2004359571
(Production method)
The dissolved (A) phase was added to the dissolved (B) phase, emulsified, and then neutralized with the (C) phase to obtain an emulsion.
[0084]
The cyclic AMP (cAMP) production inhibitors of Examples 1 to 29 described above all exhibited excellent effects in the cyclic AMP (cAMP) production inhibition effect test.
[0085]
【The invention's effect】
As described above in detail, according to the present invention, a highly safe cyclic AMP (cAMP) production inhibitor having an excellent cyclic AMP (cAMP) production inhibitory effect is provided.

Claims (1)

シクンシ科 Terminalia chebula、シクンシ科 Terminalia belerica、シソ科 Ocimum basillicum、ユキノシタ科 Bergenia ciliata、ウルシ科 Anacardium occidentale、ビワモドキ科 Dillenia indica、カンラン科 Boswellia serrata、シナノキ科 Grewia salutaris、ミソハギ科 Woodfordia floribunda、マメ科 Cassia angustifolia、クワ科 Ficus ribes、アリノトウグサ科 Gunnera macrophylla、クワ科 Ficus religiosa、ヤシ科 Areca catechu、マメ科 Stryphlinodendron barbatiman、クワ科 Ficus bengalensis、ブナ科 Quercus brachystachys、マメ科 Acacia fornensia、マメ科 Cassia fistula、パンヤ科 Salmalia malabalica、フジウツギ科 Buddleja cordata、アカネ科 Uncaria gambir、アカネ科 Uncarina tomentosa、アカネ科 Capirona decorticans、ツツジ科 Lyonia ovalifolia、モクセイ科 Maytenus krukovii、トウダイグサ科 Phyllanthus niruri、ユリ科 Smilax aristolochiaefolia、ブナ科 Quercus mexicanaから選ばれる1種または2種以上の植物、またはこれらの溶媒抽出物を有効成分として含有することを特徴とするサイクリックAMP(cAMP)産生阻害剤。Combretaceae Terminalia chebula, combretaceae Terminalia belerica, Labiatae Ocimum basillicum, Saxifragaceae Bergenia ciliata, Anacardiaceae Anacardium occidentale, dilleniaceae Dillenia indica, olivine Department of Boswellia serrata, linden family Grewia salutaris, Lythraceae Woodfordia floribunda, legumes Cassia angustifolia, Mulberry family Ficus ribes, Arino spurge family Gunnera macrophylla, Mulberry family Ficus religiosa, Palm tree Areca catechu, Legume family Strphyphrin odendron barbatiman, Moraceae Ficus bengalensis, Fagaceae Quercus brachystachys, legume Acacia fornensia, legumes Cassia fistula, bombacaceae Salmalia malabalica, Fujiutsugi Department of Buddleja cordata, Rubiaceae Uncaria gambir, Rubiaceae Uncarina tomentosa, Rubiaceae Capirona decorticans, Ericaceae Lyonia ovalifolia, Oleaceae Maytenus krukovii, Euphorbiaceae Phyllanthus nirruri, Lily Family Smilax aristolochiaefolia, Beech family Quercus A cyclic AMP (cAMP) production inhibitor comprising one or more plants selected from mexicana, or a solvent extract thereof, as an active ingredient.
JP2003157577A 2003-06-03 2003-06-03 Cyclic amp (camp) production inhibitor Withdrawn JP2004359571A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2003157577A JP2004359571A (en) 2003-06-03 2003-06-03 Cyclic amp (camp) production inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003157577A JP2004359571A (en) 2003-06-03 2003-06-03 Cyclic amp (camp) production inhibitor

Publications (1)

Publication Number Publication Date
JP2004359571A true JP2004359571A (en) 2004-12-24

Family

ID=34051240

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003157577A Withdrawn JP2004359571A (en) 2003-06-03 2003-06-03 Cyclic amp (camp) production inhibitor

Country Status (1)

Country Link
JP (1) JP2004359571A (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072756A1 (en) * 2004-01-30 2005-08-11 Suntory Limited Whitening agent
WO2008104941A3 (en) * 2007-02-28 2008-11-06 Procter & Gamble Personalcare composition comprising botanical extract of ficus benghalensis
JP2010047497A (en) * 2008-08-20 2010-03-04 B & C Laboratories Inc Elastin production promoting agent
WO2012033989A3 (en) * 2010-09-10 2012-11-29 The Procter & Gamble Company Cosmetic compositions comprising ficus serum fraction and methods to reduce the appearance of skin hyperpigmentation
WO2012034060A3 (en) * 2010-09-10 2013-01-17 Akzo Nobel Chemicals International B.V. Bioactive compositions comprising ficus serum fraction and methods to reduce the appearance of skin hyperpigmentation
JP2013147438A (en) * 2012-01-17 2013-08-01 Kose Corp cAMP PRODUCTION INHIBITOR
JP2014506596A (en) * 2011-02-22 2014-03-17 アクゾ ノーベル ケミカルズ インターナショナル ベスローテン フエンノートシャップ Composition containing bengal body, lotus and clover serum fractions (hyperpigmentation)
JP2018062481A (en) * 2016-10-12 2018-04-19 株式会社バスクリン Arbutin-containing composition, and method for inhibiting the degradation of arbutin
JP2018065774A (en) * 2016-10-21 2018-04-26 花精化学工業株式会社 Aerosol type foam pack cosmetic
CN110680858A (en) * 2019-11-29 2020-01-14 内蒙古自治区国际蒙医医院(内蒙古自治区蒙医药研究所) Application of Senden-4 in anti-tumor

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072756A1 (en) * 2004-01-30 2005-08-11 Suntory Limited Whitening agent
CN101621987B (en) * 2007-02-28 2013-08-21 宝洁公司 Personal care composition comprising botanical extract of ficus benghalensis
WO2008104941A3 (en) * 2007-02-28 2008-11-06 Procter & Gamble Personalcare composition comprising botanical extract of ficus benghalensis
CN101621987A (en) * 2007-02-28 2010-01-06 宝洁公司 Personal care composition comprising botanical extract of ficus benghalensis
US9358263B2 (en) 2007-02-28 2016-06-07 The Procter & Gamble Company Personal care composition comprising botanical extract
JP2010047497A (en) * 2008-08-20 2010-03-04 B & C Laboratories Inc Elastin production promoting agent
WO2012034060A3 (en) * 2010-09-10 2013-01-17 Akzo Nobel Chemicals International B.V. Bioactive compositions comprising ficus serum fraction and methods to reduce the appearance of skin hyperpigmentation
WO2012033989A3 (en) * 2010-09-10 2012-11-29 The Procter & Gamble Company Cosmetic compositions comprising ficus serum fraction and methods to reduce the appearance of skin hyperpigmentation
JP2014506596A (en) * 2011-02-22 2014-03-17 アクゾ ノーベル ケミカルズ インターナショナル ベスローテン フエンノートシャップ Composition containing bengal body, lotus and clover serum fractions (hyperpigmentation)
JP2013147438A (en) * 2012-01-17 2013-08-01 Kose Corp cAMP PRODUCTION INHIBITOR
JP2018062481A (en) * 2016-10-12 2018-04-19 株式会社バスクリン Arbutin-containing composition, and method for inhibiting the degradation of arbutin
JP2018065774A (en) * 2016-10-21 2018-04-26 花精化学工業株式会社 Aerosol type foam pack cosmetic
CN110680858A (en) * 2019-11-29 2020-01-14 内蒙古自治区国际蒙医医院(内蒙古自治区蒙医药研究所) Application of Senden-4 in anti-tumor

Similar Documents

Publication Publication Date Title
KR100822835B1 (en) Plant extracts and cosmetic compositions for improvement of scalp and hair
JP4233734B2 (en) Skin external preparation for whitening
CA2588131C (en) Method and composition for reducing the appearance of wrinkles
CN101653537A (en) Ceramide production accelerant
JP2003261432A (en) Skin care preparation
JP2004359571A (en) Cyclic amp (camp) production inhibitor
PT1844786E (en) Extracts of curcuma longa and their cosmetic and dermatological uses
EP2332558B1 (en) Ceramide production-accelerating agent
CN114392323A (en) Anti-glycation traditional Chinese medicine extract
JP2003212749A (en) INHIBITOR OF AGEs FORMATION AND SKIN CARE PREPARATION COMPRISING THE SAME
JP2004352658A (en) External preparation for skin
JP2003160461A (en) Skin care preparation
KR100482694B1 (en) Liposome base for trichogenousness, Cosmetic composition for trichogenousness containing the same, and Method for improving absorptance of natural ingredients for trichogenousness using the same
KR101065356B1 (en) Cosmetic application of defatted Camellia japonica Seed debris and seed coats and its extract
JP2004352659A (en) External preparation for skin for bleaching
WO2017035775A1 (en) Product containing rhodiola rosea extract and ginkgo biloba extract, preparation method therefor, and use thereof
JP5717958B2 (en) Ceramide production promoter, and pharmaceutical composition, skin external preparation, cosmetic composition and cosmetic using the ceramide production promoter
CN110882189A (en) Use of extract of Graptopetalum paraguayense in cosmetics
CN105267082A (en) Impatiens balsamina extract and application thereof
KR100798252B1 (en) C-Kit activation inhibitor, skin whitening compound and composition for skin whitening containing the same
KR20050092313A (en) Skin whitening cosmetic containing a herb extract with inhibitory activity of melanin formation
KR20030063450A (en) Hair growth inhibitors and compositions containing the same
KR20170121358A (en) Cosmetic composition for improvement or prevention anti-dark circle
KR20080111299A (en) Whitening composition for external applications to the skin containing premature kaempferol-3,7-o-alpha-l-dirhamnopyranoside
JP2000119133A (en) Skin lotion for bleaching

Legal Events

Date Code Title Description
A300 Withdrawal of application because of no request for examination

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20060905